PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC).

Authors

Lee Schwartzberg

The West Clinic

Lee Schwartzberg , Fernando Rivera , Meinolf Karthaus , Gianpiero Fasola , Jean-Luc Canon , Hua Yu , William Go

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

First Author: Allen Lee Cohn

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

First Author: J. Hecht

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.

First Author: Kazuomi Ueshima

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).

First Author: Vaibhav Sahai